Join the next opnMe.com Online Seminar
November 29, 2022 – 4 pm CET / 10 am EST
– The journey of an opnMe PROTAC, from bench to a new therapeutic target discovery –
Illuminating the role of SMARCA2/4 in childhood cancer by targeted protein degradation with ACBI1 from Boehringer Ingelheim’s open innovation portal, opnMe.com
In recent years, the emergence of PROTAC technology, which uses molecules with the ability to degrade unwanted proteins in the cell, has opened new possibilities to expand the therapeutic targets used to treat cancer. ACBI1, the molecule we have selected for our next opnMe live seminar, has been crucial in demonstrating this potential.
ACBI1 was developed as part of a collaboration between the University of Dundee, School of Life Sciences, and Boehringer Ingelheim. After its publication in Nature Chemical Biology, this potent degrader of the BAF complex ATPases SMARCA2 and SMARCA4 was released on Boehringer Ingelheim´s open innovation platform, opnMe.com. This molecule could not only deliver an acute and profound SMARCA2/4 knockdown at a cellular level, but its data were also deemed suitable for in vivo studies. ACBI1 attracted the attention of researchers working with rhabdomyosarcoma, a group of childhood malignancies related to somatic mutations in the chromatin remodeling BAF complex, particularly of SMARCA2 and 4.
Next Tuesday, November 29th, join us to follow ACBI1 journey from the perspective of the talented scientists who developed it and applied it to the discovery of therapeutic targets. Alessio Ciulli from the Center of Targeted Protein Degradation, University of Dundee, and Manfred Koegl, Cancer Research Boehringer Ingelheim, will tell us how they created this novel PROTAC, able to degrade SMARCA 2 and 4 cooperatively. Charles Keller from the Children’s Cancer Therapy Development Institute, in Portland, Oregon, and Beat Schäfer from the University Children’s Hospital Zurich, who independently identified SMARCA4 as a tumor cell dependency factor, will discuss how the selectivity of ACBI1 was used to unveil a new therapeutic target in alveolar rhabdomyosarcoma.
REGISTER today to learn about the exciting story of ACBI1: